Close Menu

intellectual property

The University of Maryland, Baltimore is now participating in Horizon's "Targeting Cancer Consortium," in which the company supplies its gene-engineering platform to academic researchers, who create cellular disease models that Horizon in-licenses and sells to drug makers.

NKT licensed the IP from Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Massachusetts General Hospital. As a result, each of the Harvard Med-affiliated institutes has been awarded an undisclosed equity stake in the company.

The deal is a result of a nearly three-year research partnership between Aphios and LSUHSC-S, and is the latest product of a concerted effort at LSUHSC-S to ramp up collaboration between its faculty and industry.

The deal brings to six the number of academic institutions from which Fate has licensed IP related to using small molecules to induce pluripotency in stem cells for therapeutic effect, drug discovery, and matched cell-replacement therapies.

The patent, called “Fragment Complementation Assays for G Protein-Coupled Receptors and Their Signaling Pathways,” solidifies Odyssey’s position in complex-based assays, and adds depth to its IP coverage in these two areas, an Odyssey official told CBA News this week.

Pages

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.